PT  - JOURNAL ARTICLE
AU  - Swaminathan P. Iyer
AU  - Joe Ensor
AU  - Kartik Anand
AU  - Patrick Hwu
AU  - Vivek Subbiah
AU  - Christopher Flowers
AU  - Rudragouda Channappanavar
TI  - Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes
AID  - 10.1101/2020.04.19.20062174
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.19.20062174
4099  - http://medrxiv.org/content/early/2020/04/24/2020.04.19.20062174.short
4100  - http://medrxiv.org/content/early/2020/04/24/2020.04.19.20062174.full
AB  - The emergent global pandemic caused by the rapid spread of Severe Acute Respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has led to increased mortality and negatively impacted day to day activities of humankind within a short period of time. As the data is rapidly emerging from earlier outbreak locations around the world, there are efforts to assimilate this with the knowledge from prior epidemics and find rapid solutions for this. One of the observations and a recurring theme is the disproportionate differences in the incidence of infection and the consequent mortality between males and females. We, therefore, analyzed retrospective datasets from the previous epidemics and the ongoing pandemic in order to address these differences in clinical outcomes. The data shows that even though the infection rates are similar, the odds ratio of male mortality remains high, indicating a divergence in the crosstalk between the three pathogenic human Coronavirus (hCoVs)-the SARS-CoV, MERS-CoV and the SARS-CoV-2 and immune effectors in the two sexes. One proximate cause is the sex-specific modulation of the X-linked genes that can influence susceptibility to infection. Future studies are needed to confirm these findings, which can form the basis for developing rational strategies for ending the current and preventing future pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudies chosen for these analyses were based on the availability of the sample size, and that of detailed patient demographics, including gender-associated incidence and mortality in peer- reviewed journals.